phenindione has been researched along with Thromboembolism in 69 studies
Phenindione: An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)
Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a multicenter, prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban with vitamin K antagonists in patients with prevalent or incident atrial fibrillation as the indication for oral anticoagulation after successful TAVR." | 9.41 | Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. ( Anderson, R; Baber, U; Boersma, E; Capranzano, P; Chen, C; Dangas, GD; Duggal, A; Hambrecht, R; Hayashida, K; Hengstenberg, C; Jin, J; Kim, HS; Laeis, P; Lang, I; Lanz, H; López-Otero, D; Mehran, R; Meincke, F; Möllmann, H; Moreno, R; Nombela-Franco, L; Nordbeck, P; Ohlmann, P; Pilgrim, T; Rodés-Cabau, J; Saito, S; Shawl, F; Thiele, H; Unverdorben, M; Valgimigli, M; Van Mieghem, NM; Veltkamp, R; Vranckx, P; Watanabe, Y; Yamamoto, M; Zamorano, JL, 2021) |
| "The combination of aspirin with anticoagulant is associated with increased bleeding in elderly atrial fibrillation patients." | 9.09 | Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). ( Chaumet-Riffaud, P; Derumeaux, G; Lacomblez, L; Lardoux, H; Lechat, P; Lecompte, T; Maillard, L; Mallet, A; Mas, JL; Mentre, F; Pisica, G; Pousset, F; Raynaud, P; Sanchez, P; Solbes-Latourette, S, 2001) |
| "We conducted a multicenter, prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban with vitamin K antagonists in patients with prevalent or incident atrial fibrillation as the indication for oral anticoagulation after successful TAVR." | 5.41 | Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. ( Anderson, R; Baber, U; Boersma, E; Capranzano, P; Chen, C; Dangas, GD; Duggal, A; Hambrecht, R; Hayashida, K; Hengstenberg, C; Jin, J; Kim, HS; Laeis, P; Lang, I; Lanz, H; López-Otero, D; Mehran, R; Meincke, F; Möllmann, H; Moreno, R; Nombela-Franco, L; Nordbeck, P; Ohlmann, P; Pilgrim, T; Rodés-Cabau, J; Saito, S; Shawl, F; Thiele, H; Unverdorben, M; Valgimigli, M; Van Mieghem, NM; Veltkamp, R; Vranckx, P; Watanabe, Y; Yamamoto, M; Zamorano, JL, 2021) |
| "The combination of aspirin with anticoagulant is associated with increased bleeding in elderly atrial fibrillation patients." | 5.09 | Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). ( Chaumet-Riffaud, P; Derumeaux, G; Lacomblez, L; Lardoux, H; Lechat, P; Lecompte, T; Maillard, L; Mallet, A; Mas, JL; Mentre, F; Pisica, G; Pousset, F; Raynaud, P; Sanchez, P; Solbes-Latourette, S, 2001) |
| " We extracted data for adults (aged ≥18 years) with non-valvular atrial fibrillation who received their first prescription for a vitamin K antagonist (fluindione, warfarin, or acenocoumarol) between Jan 1, 2011, and Nov 30, 2012, and who were either switched to a NOAC (dabigatran or rivaroxaban) or maintained on the vitamin K antagonist." | 3.81 | Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. ( Bertrand, M; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M, 2015) |
| " The mean phenindione dosage was 72 mg." | 2.63 | Assessment of short-anticoagulant administration after cardiac infarction. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. ( , 1969) |
| "Phenindione has been the anticoagulant of choice." | 1.31 | Standard versus low-level anticoagulation combined to low-dose dipyridamole after mitral valve replacement. ( Allam, H; Awad, A; Hassaballah, F; Hassouna, A, 2000) |
| "Thromboembolism was found to be the leading complication affecting the survival rate and the stability of good results in the late postoperative period." | 1.26 | [Thromboembolic complications after aortic valve prosthesis]. ( Sharykin, AS, 1977) |
| "Bacterial endocarditis was a serious complication and accounted for three hospital and five long-term deaths." | 1.25 | Immediate and long-term results of aortic valve replacent with University of Cape Town aortic valve prosthesis. ( Barnard, CN; Beck, W; Hewitson, RP; Schrire, V, 1970) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 60 (86.96) | 18.7374 |
| 1990's | 1 (1.45) | 18.2507 |
| 2000's | 5 (7.25) | 29.6817 |
| 2010's | 2 (2.90) | 24.3611 |
| 2020's | 1 (1.45) | 2.80 |
| Authors | Studies |
|---|---|
| Van Mieghem, NM | 1 |
| Unverdorben, M | 1 |
| Hengstenberg, C | 1 |
| Möllmann, H | 1 |
| Mehran, R | 1 |
| López-Otero, D | 1 |
| Nombela-Franco, L | 1 |
| Moreno, R | 1 |
| Nordbeck, P | 1 |
| Thiele, H | 1 |
| Lang, I | 1 |
| Zamorano, JL | 1 |
| Shawl, F | 1 |
| Yamamoto, M | 1 |
| Watanabe, Y | 1 |
| Hayashida, K | 1 |
| Hambrecht, R | 1 |
| Meincke, F | 1 |
| Vranckx, P | 1 |
| Jin, J | 1 |
| Boersma, E | 1 |
| Rodés-Cabau, J | 1 |
| Ohlmann, P | 1 |
| Capranzano, P | 1 |
| Kim, HS | 1 |
| Pilgrim, T | 1 |
| Anderson, R | 1 |
| Baber, U | 1 |
| Duggal, A | 1 |
| Laeis, P | 1 |
| Lanz, H | 1 |
| Chen, C | 1 |
| Valgimigli, M | 1 |
| Veltkamp, R | 1 |
| Saito, S | 1 |
| Dangas, GD | 1 |
| Valdelièvre, E | 1 |
| Quéré, I | 1 |
| Caré, B | 1 |
| Laroche, JP | 1 |
| Schved, JF | 1 |
| Bouillon, K | 1 |
| Bertrand, M | 1 |
| Maura, G | 1 |
| Blotière, PO | 1 |
| Ricordeau, P | 1 |
| Zureik, M | 1 |
| BROWN, KW | 1 |
| MACMILLAN, RL | 1 |
| McCABE, ES | 1 |
| FITTIPOLDI, J | 1 |
| REMDE, W | 1 |
| CHALMERS, JN | 1 |
| DIXON, MF | 1 |
| POLACK, W | 1 |
| SALOMON, S | 1 |
| SIBLEY, JJ | 1 |
| CASHIN, PJ | 1 |
| KIM, CS | 1 |
| BEYREDER, J | 1 |
| KRASA, F | 1 |
| HAASE, HW | 1 |
| BUSCHER, G | 1 |
| NEILSON, JM | 1 |
| MOLLISON, AW | 1 |
| BLAUSTEIN, A | 1 |
| CASTIGLIONI, G | 1 |
| TAMBORINI, G | 1 |
| BLEKSMIT, ZD | 1 |
| KOTOVSHCHIKOVA, MA | 1 |
| MARTYNOVA, NV | 1 |
| SEAMAN, AJ | 3 |
| POLLER, L | 1 |
| O'BRIEN, PK | 1 |
| DOICHINOV, A | 1 |
| SOLONEN, KA | 1 |
| PUGLIESE, F | 1 |
| SILVESTRI, G | 1 |
| FAGAN, DG | 1 |
| NAMBIAR, R | 1 |
| LENTIN, M | 1 |
| MCQUILLAN, WM | 1 |
| GRISWOLD, HE | 2 |
| REAUME, RB | 2 |
| RITZMAN, LW | 1 |
| RICE-WRAY, E | 1 |
| NAKAMURA, RM | 1 |
| KUNITAKE, GM | 1 |
| FUJITA, K | 1 |
| REILLY, EB | 1 |
| PERSSON, BM | 1 |
| MICHAELS, L | 1 |
| MOSCHOS, CB | 1 |
| WONG, PC | 1 |
| SISE, HS | 1 |
| FIELD, JB | 1 |
| GOLDFARB, MS | 1 |
| WARE, AG | 1 |
| GRIFFITH, GC | 1 |
| Saligari, E | 1 |
| Belle, L | 1 |
| Berry, C | 1 |
| Gonod, M | 1 |
| Poiré, V | 1 |
| Picard, A | 1 |
| Vialle, E | 1 |
| Desjoyaux, E | 1 |
| Lechat, PP | 1 |
| Vavilova, TV | 1 |
| Sirotkina, OV | 1 |
| Razorenov, GI | 1 |
| Razorenova, TS | 1 |
| Emanuél', VL | 1 |
| Gritsenko, VV | 1 |
| Orlovskiĭ, PI | 1 |
| Doĭnikov, DN | 1 |
| Sharafutdinov, VE | 1 |
| Karpov, SA | 1 |
| Kuznetsov, AA | 1 |
| Kadinskaia, MI | 1 |
| Cazaux, V | 1 |
| Gauthier, B | 1 |
| Elias, A | 1 |
| Lefebvre, D | 1 |
| Tredez, J | 1 |
| Nguyen, F | 1 |
| Cambus, JP | 1 |
| Boneu, B | 1 |
| Boccalon, H | 1 |
| Hassouna, A | 1 |
| Allam, H | 1 |
| Awad, A | 1 |
| Hassaballah, F | 1 |
| Lechat, P | 1 |
| Lardoux, H | 1 |
| Mallet, A | 1 |
| Sanchez, P | 1 |
| Derumeaux, G | 1 |
| Lecompte, T | 1 |
| Maillard, L | 1 |
| Mas, JL | 1 |
| Mentre, F | 1 |
| Pousset, F | 1 |
| Lacomblez, L | 1 |
| Pisica, G | 1 |
| Solbes-Latourette, S | 1 |
| Raynaud, P | 1 |
| Chaumet-Riffaud, P | 1 |
| Domenet, JG | 1 |
| Evans, DW | 1 |
| Lawson, DH | 1 |
| Lowe, GD | 1 |
| Joly, F | 1 |
| Valty, J | 1 |
| Emar, A | 1 |
| Morris, GK | 1 |
| Lavrinovich, TS | 1 |
| Petukhova, LI | 1 |
| Slutskiĭ, LI | 2 |
| Sharykin, AS | 1 |
| Lavrinovitsch, TS | 1 |
| Petuchova, LI | 1 |
| Rado, Iu | 1 |
| Chikvashvili, DI | 1 |
| Wickramasinghe, LS | 1 |
| Basu, SK | 1 |
| Bansal, SK | 1 |
| Coelho, E | 1 |
| Ritland, S | 1 |
| Lygren, T | 1 |
| Straub, PW | 1 |
| Ritzmann, L | 1 |
| Gordon-Smith, IC | 1 |
| Wright, IS | 1 |
| Dabels, J | 1 |
| Konrad, H | 1 |
| Schulz, K | 1 |
| Kubicek, F | 1 |
| Praschl, E | 1 |
| Nour-Eldin, F | 1 |
| Lewis, FJ | 1 |
| Buxbaum, A | 1 |
| Aygen, MM | 1 |
| Shahin, W | 1 |
| Levy, MJ | 1 |
| Ekerling, B | 1 |
| Duncan, ID | 1 |
| Coyle, MG | 1 |
| Walker, J | 1 |
| Wingfield, JG | 1 |
| Fiori, W | 2 |
| Civai, O | 2 |
| Lenzi, L | 2 |
| Albert, L | 1 |
| Horn, G | 1 |
| Schrire, V | 1 |
| Beck, W | 1 |
| Hewitson, RP | 1 |
| Barnard, CN | 1 |
| Raby, C | 1 |
| Jenkins, BS | 1 |
| Braimbridge, MV | 1 |
| Keller, J | 1 |
| Goinard, P | 1 |
| Thouverez, JP | 1 |
| Belleville, JF | 1 |
| Croizat, P | 1 |
| Sevitt, S | 1 |
| Baly, Y | 1 |
| Rex, JO | 1 |
| Andersch, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation[NCT02943785] | Phase 3 | 1,426 participants (Actual) | Interventional | 2017-03-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A composite of clinical adverse events included cardiovascular death, MI ischemic stroke, SEE, valve thrombosis, and major bleeding as defined by ISTH criteria. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 151 |
| Vitamin K Antagonist (VKA) | 123 |
Major adverse cardiac and cerebrovascular events (MACCE) is defined as the composite of all-cause death (excluding adjudicated non-cardiac death), MI, stroke (ischemic, hemorrhagic, or undetermined), or repeat coronary revascularization of the target lesion (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 86 |
| Vitamin K Antagonist (VKA) | 80 |
Major adverse cardiac events (MACE) is defined as the composite of all-cause death (excluding adjudicated non-cardiac death), MI, or repeat coronary revascularization of the target lesion. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 61 |
| Vitamin K Antagonist (VKA) | 53 |
ISTH Bleeding Criteria for Major Bleeding are defined as clinically overt bleeding that is associated with: a fall in hemoglobin of 2 g/dL (1.24 mmol/L) or more, or a transfusion of 2 or more units of whole blood or packed red blood cells, or symptomatic bleeding into a critical site or organ such as intracranial, intraspinal, intraocular, retroperitoneal, pericardial, intra-articular, or intramuscular with compartment syndrome, or a fatal outcome. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 98 |
| Vitamin K Antagonist (VKA) | 68 |
Peri-procedural MI was defined as new ischemic symptoms or signs and elevated cardiac biomarkers within 72 hours after index procedure, consisting of at least one sample post-procedure with a peak value exceeding 15x as the upper reference limit (URL) for troponin or 5x for CK-MB. Spontaneous MI is defined as any one of the following: Detection of rise and/or fall of cardiac biomarkers with at least one value above the 99th percentile URL, together with the evidence of myocardial ischemia with at least one of the following: Symptoms of ischemia; ECG changes indicative of new ischemia; New pathological Q-waves in at least two contiguous leads; Imaging evidence of a new loss of viable myocardium or new wall motion abnormality; Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied by new ST elevation or new left bundle branch block, and/or evidence of fresh thrombus; Pathological findings of an acute MI. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 12 |
| Vitamin K Antagonist (VKA) | 7 |
The composite endpoint net adverse clinical events (NACE) included all-cause death, myocardial infarction (MI), ischemic stroke, systemic embolic events (SEE), valve thrombosis, and major bleeding per definition of the International Society on Thrombosis and Haemostasis (ISTH]. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 170 |
| Vitamin K Antagonist (VKA) | 157 |
Systemic thromboembolism [non-central nervous system] is defined as abrupt vascular insufficiency of an extremity or organ associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms, (e.g., trauma, atherosclerosis, instrumentation). (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 2 |
| Vitamin K Antagonist (VKA) | 3 |
Valve thrombosis was defined as any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 0 |
| Vitamin K Antagonist (VKA) | 0 |
The composite endpoint of net adverse event clinical events (NACE) included all-cause death, MI, ischemic stroke, SEE, valve thrombosis, and major bleeding based on Bleeding Academic Research Consortium (BARC) Type 3 or 5 criteria. Major bleeding by BARC criteria was defined as Type 3: clinical, laboratory, and/or imaging evidence of bleeding with provider responses; Type 3a: any transfusion with overt bleeding; overt bleeding plus Hb drop of 3 to < 5 g/dL; Type 3b: overt bleeding plus Hb drop ≥ 5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring intravenous vasoactive drugs; Type 3c: intracranial hemorrhage; subcategories confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision; Type 5: fatal bleeding; Type 5a: probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious; Type 5b: definite fatal bleeding; overt bleeding or autopsy or imaging confirmation (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Composite endpoint NACE (BARC Type 3 or 5) | Major bleeding (BARC Type 3 or 5) | |
| Edoxaban | 164 | 89 |
| Vitamin K Antagonist (VKA) | 151 | 57 |
The composite endpoint of net adverse event clinical events (NACE) included all-cause death, MI, ischemic stroke, SEE, valve thrombosis, and major bleeding based on Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO). GUSTO criteria was defined as the following: severe or life threatening: intracerebral hemorrhage or resulting in substantial hemodynamic compromise requiring treatment and moderate: requiring blood transfusion but not resulting in hemodynamic compromise. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Composite endpoint NACE (GUSTO) | Severe or life threatening and moderate bleeding (GUSTO) | |
| Edoxaban | 160 | 82 |
| Vitamin K Antagonist (VKA) | 146 | 51 |
The composite endpoint of net adverse event clinical events (NACE) included all-cause death, myocardial infarction (MI), ischemic stroke, systemic embolic events (SEE), valve thrombosis, and major bleeding based on Thrombolysis in Myocardial Infarction (TIMI) criteria. Bleeding by TIMI criteria was defined as the following: (1) Major, any intracranial hemorrhage or any clinically overt bleeding, (including bleeding evident in imaging studies) associated with a fall of hemoglobin (Hb) of ≥ 5g/dL or fatal bleeding and (2) Minor, any clinically overt bleeding associated with a fall in Hb ≥ 3g/dL but < 5 g/dL. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Composite endpoint NACE (TIMI) | Composite of major and minor bleeding (TIMI) | |
| Edoxaban | 154 | 72 |
| Vitamin K Antagonist (VKA) | 141 | 42 |
Stroke events are categorized as any stroke, fatal stroke, and non-fatal stroke. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Any stroke (ischemic, hemorrhagic, or undetermined) | Fatal stroke (ischemic, hemorrhagic, or undetermined) | Non-fatal stroke (ischemic, hemorrhagic, or undetermined) | |
| Edoxaban | 29 | 4 | 25 |
| Vitamin K Antagonist (VKA) | 35 | 3 | 32 |
6 reviews available for phenindione and Thromboembolism
| Article | Year |
|---|---|
[Evaluation of an education program of patients undergoing oral anticoagulation treatment].
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Chi-Square Distribution; Data Interpretat | 2003 |
Aspirin--anticoagulant combination in patients with non valvular atrial fibrillation commentary on the FFAACS study results.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; Phenindione; Thromb | 2003 |
Clinical use of anticoagulant drugs.
Topics: Administration, Oral; Ancrod; Anticoagulants; Coumarins; Heparin; Humans; Phenindione; Thromboemboli | 1977 |
[Indications for and hazards of anticoagulant therapy].
Topics: Anticoagulants; Cerebrovascular Disorders; Coumarins; Diabetic Angiopathies; Disseminated Intravascu | 1970 |
A critical evaluation of anticoagulant therapy.
Topics: Anticoagulants; Blood Coagulation Tests; Cerebral Hemorrhage; Cerebrovascular Disorders; Coumarins; | 1969 |
[Prevention of postoperative thromboembolism with phenylindandione].
Topics: Humans; Phenindione; Postoperative Complications; Thromboembolism | 1964 |
7 trials available for phenindione and Thromboembolism
| Article | Year |
|---|---|
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Topics: 4-Hydroxycoumarins; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibito | 2021 |
Aspirin--anticoagulant combination in patients with non valvular atrial fibrillation commentary on the FFAACS study results.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; Phenindione; Thromb | 2003 |
Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS).
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship | 2001 |
[Clinical trial of indirect-action anticoagulants in orthopedics and traumatology].
Topics: Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Fractures, Bone; Humans; Joint Diseases; Mid | 1976 |
Comparison of efficacy of 3 and 12 months' anticoagulant therapy after myocardial infarction. A controlled clinical trial.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Cerebral Hemorrhage; Clinical Trials as Topic; | 1969 |
Long-term anticoagulant prophylaxis after myocardial infarction.
Topics: Aftercare; Anticoagulants; Female; Hospitalization; Humans; Long-Term Care; Male; Middle Aged; Myoca | 1969 |
Assessment of short-anticoagulant administration after cardiac infarction. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myoca | 1969 |
57 other studies available for phenindione and Thromboembolism
| Article | Year |
|---|---|
[Time in therapeutic range (TTR) and follow-up of patients on vitamin K antagonist: A cohort analysis].
Topics: Acenocoumarol; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Coho | 2018 |
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hem | 2015 |
The anticoagulant effect of phenylindanedione in thromboembolic disorders.
Topics: Anticoagulants; Humans; Phenindione; Prothrombin Time; Thromboembolism; Vitamin K | 1953 |
Current status of use of phenylindanedione: case report.
Topics: Myocardial Infarction; Phenindione; Thromboembolism | 1953 |
[Anticoagulant therapy of thromboembolic diseases with special reference to phenindione].
Topics: Anticoagulants; Humans; Phenindione; Thromboembolism | 1953 |
Antagonistic effect of oral vitamin K1 on the action of ethyl biscoumacetate and phenylindanedione.
Topics: Antifibrinolytic Agents; Coumarins; Ethyl Biscoumacetate; Heparin Antagonists; Naphthoquinones; Phen | 1954 |
Experience with hedulin an effective oral anticoagulant.
Topics: Anticoagulants; Phenindione; Thromboembolism | 1954 |
Use of phenylindanedione in acute thromboembolic disease; observations in 35 patients.
Topics: Acute Disease; Humans; Phenindione; Thromboembolism | 1954 |
[Clinical experience in antithrombotic therapy with phenylindandion].
Topics: Fibrinolytic Agents; Phenindione; Thromboembolism | 1954 |
[Treatment of thrombosis with 2-phenylinandion].
Topics: Humans; Phenindione; Thromboembolism; Thrombosis | 1955 |
Clinical evaluation of three anticoagulants in thrombo-embolic disease.
Topics: Anticoagulants; Coumarins; Embolism; Ethyl Biscoumacetate; Humans; Phenindione; Prothrombin Time; Th | 1957 |
A preliminary report on the clinical use of a new anticoagulant (miradon).
Topics: Anticoagulants; Phenindione; Thromboembolism | 1958 |
[Prolonged anticoagulant therapy of arterial and venous diseases with thrombo-embolic tendency].
Topics: Anticoagulants; Dicumarol; Embolism; Heparin; Humans; Phenindione; Thromboembolism; Vascular Disease | 1958 |
[Experimental-clinical study of a new anticoagulant phenylindandione].
Topics: Anticoagulants; Biomedical Research; Humans; Phenindione; Thromboembolism | 1958 |
p-Bromindione: a new, potent, long-acting oral anticoagulant drug.
Topics: Anticoagulants; Indans; Phenindione; Thromboembolism | 1961 |
Chlorphenindione--a new longacting oral anticoagulant.
Topics: Anticoagulants; Phenindione; Thromboembolism | 1962 |
[ANTICOAGULANTS IN THE TREATMENT OF MYOCARDIAL INFARCT].
Topics: Anticoagulants; Coumarins; Heparin; Humans; Myocardial Infarction; Phenindione; Thromboembolism; War | 1963 |
PROPHYLACTIC ANTICOAGULANT THERAPY IN THE TREATMENT OF LOWER LIMB FRACTURES.
Topics: Anticoagulants; Blood Coagulation Tests; Femoral Fractures; Femoral Neck Fractures; Fibula; Fracture | 1963 |
[ANTICOAGULANT THERAPY OF MYOCARDIAL INFARCT].
Topics: Angina Pectoris; Anticoagulants; Cardiac Complexes, Premature; Heart Failure; Heparin; Humans; Myoca | 1963 |
PREVENTION OF THROMBOEMBOLIC PHENOMENA FOLLOWING OPERATIONS ON THE NECK OF THE FEMUR.
Topics: Arthroplasty; Femoral Neck Fractures; Fracture Fixation; Hemorrhage; Humans; Immobilization; Phenind | 1964 |
FIBRINOLYSIN THERAPY IN ARTERIAL THROMBO-EMBOLISM.
Topics: Embolism; Fibrinolysin; Heparin; Humans; Phenindione; Radiography; Thromboembolism | 1964 |
EXPERIENCES WITH PROPHYLACTIC ANTI-COAGULATION IN FEMORAL NECK FRACTURES.
Topics: Cerebrovascular Disorders; Ecchymosis; Femoral Neck Fractures; Gastrointestinal Hemorrhage; Geriatri | 1964 |
PROPHYLACTIC ANTICOAGULANT THERAPY FOR CORONARY ARTERY DISEASE. A SEVEN-YEAR CONTROLLED STUDY.
Topics: Anticoagulants; Biomedical Research; Coronary Artery Disease; Coronary Disease; Humans; Myocardial I | 1964 |
AN ASSESSMENT OF LONG-TERM ANTICOAGULANT ADMINISTRATION AFTER CARDIAC INFARCTION. SECOND REPORT OF THE WORKING PARTY ON ANTICOAGULANT THERAPY IN CORONARY THROMBOSIS TO THE MEDICAL RESEARCH COUNCIL.
Topics: Anticoagulants; Biomedical Research; Coronary Thrombosis; Electrocardiography; Humans; Infarction; M | 1964 |
PLASMA-FIBRINOGEN LEVELS AFTER LONG-TERM WARFARIN THERAPY.
Topics: Coagulants; Fibrinogen; Humans; Pharmacology; Phenindione; Plasma; Thromboembolism; Warfarin | 1964 |
[MORTALITY IN FEMORAL NECK FRACTURES AND VALUE OF PREVENTIVE DICUMAROL TREATMENT].
Topics: 4-Aminobenzoic Acid; Aminobenzoates; Bronchopneumonia; Cerebral Hemorrhage; Cerebrovascular Disorder | 1964 |
CANCER INCIDENCE AND MORTALITY IN PATIENTS HAVING ANTICOAGULANT THERAPY.
Topics: Acenocoumarol; Aged; Anticoagulants; Cerebrovascular Disorders; Coronary Disease; Dicumarol; Drug Th | 1964 |
CONTROLLED STUDY OF THE EFFECTIVE LEVEL OF LONG-TERM ANTICOAGULATION.
Topics: Anticoagulants; Biomedical Research; Blood Coagulation Tests; Cerebrovascular Disorders; Coronary Di | 1964 |
Dipaxin: 2-diphenylacetyl-1,3-indandione; clinical evaluation of a new anticoagulant.
Topics: Anticoagulants; Indans; Phenindione; Thromboembolism | 1955 |
[The influence of hereditary thrombophilic mechanisms on the degree of permanent intravascular coagulation in patients with artificial heart valves].
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Factor V; Female; Gen | 2004 |
Predicting daily maintenance dose of fluindione, an oral anticoagulant drug.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Algorithms; Anticoagulants; Female; Humans; Ma | 1996 |
Standard versus low-level anticoagulation combined to low-dose dipyridamole after mitral valve replacement.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Child; Dipyridamole; Drug Therapy, Combinat | 2000 |
Prophylactic anticoagulation.
Topics: Humans; Phenindione; Thromboembolism; Time Factors; Warfarin | 1976 |
[Long-term anticoagulant therapy in subjects over 75 years of age. 100 cases].
Topics: Age Factors; Aged; Arteriosclerosis Obliterans; Coronary Disease; Humans; Intracranial Embolism and | 1977 |
Oral anticoagulant prophylaxis against venous thrombolism.
Topics: Administration, Oral; Anticoagulants; Female; Humans; Phenindione; Postoperative Complications; Preg | 1978 |
[Thromboembolic complications after aortic valve prosthesis].
Topics: Adolescent; Adult; Aortic Valve; Female; Follow-Up Studies; Heart Valve Prosthesis; Humans; Male; Mi | 1977 |
[A comparative investigation of acetylsalicyclic acid and indirect anticoagulants for the prophylaxis of venous thromboses in patients with an orthopedic-traumatologic case history (author's transl)].
Topics: Aspirin; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteotomy; Phenindione; Postoperative C | 1976 |
[Effect of long-term anticoagulant and antithrombocytic therapy on the size of intracavitary thrombus and the incidence of thromboembolic complications in patients with acute myocardial infarction].
Topics: Aspirin; Heart Diseases; Humans; Myocardial Infarction; Phenindione; Thromboembolism; Thrombosis; Ti | 1989 |
Long-term oral anticoagulant therapy in elderly patients.
Topics: Aged; Aged, 80 and over; Blood Coagulation Tests; Dose-Response Relationship, Drug; Humans; Long-Ter | 1988 |
[Anticoagulants].
Topics: Anticoagulants; Blood Coagulation Tests; Dicumarol; Fibrinolytic Agents; Heparin; Humans; Phenindion | 1968 |
Diagnosis, prevention and management of thromboembolism. Nonmechanical methods of prevention.
Topics: Anticoagulants; Dextrans; Fibrinogen; Heparin; Humans; Iodine Radioisotopes; Phenindione; Postoperat | 1974 |
[On long term treatment of heart infarction with anticoagulants].
Topics: Aged; Anticoagulants; Ethyl Biscoumacetate; Hemorrhage; Humans; Long-Term Care; Middle Aged; Myocard | 1968 |
[Clinical experiences with anticoagulant long term treatment of predominantly cardiologic patients].
Topics: Acenocoumarol; Adult; Aged; Angina Pectoris; Anticoagulants; Coronary Disease; Coumarins; Female; He | 1968 |
Tolerance to phenindione of patients with different thromboembolic disorders.
Topics: Adolescent; Adult; Aged; Blood Coagulation; Child; Drug Tolerance; Female; Hemorrhage; Humans; Male; | 1964 |
Pregnancy in patients with prosthetic heart valves.
Topics: Abortion, Missed; Abortion, Spontaneous; Adult; Anticoagulants; Female; Fetal Death; Fetus; Heart Va | 1971 |
Management and treatment of 34 cases of antepartum thromboembolism.
Topics: Age Factors; Blood Group Antigens; Dextrans; Diethylstilbestrol; Female; Hemoglobinometry; Heparin; | 1971 |
Anticoagulation for antenatal thrombo-embolic disease.
Topics: Delivery, Obstetric; Female; Heparin; Humans; Phenindione; Postpartum Hemorrhage; Pregnancy; Pregnan | 1969 |
[Prevention of thromboembolism with Athrombon after suprapubic transvesical prostatectomy].
Topics: Hematuria; Humans; Male; Phenindione; Postoperative Complications; Prostatectomy; Thromboembolism | 1969 |
Immediate and long-term results of aortic valve replacent with University of Cape Town aortic valve prosthesis.
Topics: Adolescent; Adult; Aged; Alloys; Anemia, Hemolytic; Angina Pectoris; Aortic Valve; Aortic Valve Insu | 1970 |
[Physiologic and physiopathologic bases of a rational anticoagulant therapy].
Topics: Anticoagulants; Heparin; Humans; Phenindione; Thromboembolism | 1970 |
Management of anticoagulant therapy during pregnancy in patients with prosthetic heart valves.
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Aortic Valve; Aortic Valve Insufficiency; Female | 1971 |
[Minor gynecologic surgery with athrombon treatment. 1].
Topics: Female; Genital Diseases, Female; Humans; Minor Surgical Procedures; Phenindione; Postoperative Comp | 1967 |
[An effective heparin treatment by subcutaneous route in general surgery].
Topics: Heparin; Humans; Injections, Subcutaneous; Phenindione; Thromboembolism | 1967 |
Thromboembolism and its prevention.
Topics: Aged; Anticoagulants; Fractures, Bone; Hip Injuries; Humans; Phenindione; Postoperative Complication | 1968 |
[On the use of phenyl-2-indane-dione-1-3 in the prevention of thromboembolism in gynecologic surgery].
Topics: Anticoagulants; Female; Genital Diseases, Female; Humans; Phenindione; Postoperative Complications; | 1968 |
[The prevention of postoperative thromboembolism with phenylindandione].
Topics: Humans; Phenindione; Postoperative Complications; Thromboembolism | 1966 |
[On the treatment of thromboembolic diseases with the new medium long-term anticoagulant Chlorathrombone].
Topics: Humans; Phenindione; Thromboembolism | 1966 |